HGG Immuno Group

HGG Immuno is a clinical-stage biotechnology company dedicated to developing transformative immunotherapies for patients suffering from high-grade gliomas, including glioblastoma multiforme. The company's core technology focuses on dendritic cell vaccines that are engineered to target Cytomegalovirus (CMV) antigens, which are specifically expressed within these aggressive brain tumors. By enhancing the migration of dendritic cells to lymphoid tissues, HGG Immuno aims to trigger a potent and durable anti-tumor immune response. Their lead program is currently undergoing Phase 2 clinical evaluation, representing a significant effort to address the high unmet medical need in neuro-oncology. The company leverages research originating from the University of Florida to advance its pipeline of precision immunotherapies.